Pharma and Biotech
Appointment of Phase I Clinical Trial CRO | 11-Apr-2024 | 11:26 | RNS |
Appointment of Hybridan as Adviser | 18-Mar-2024 | 07:00 | RNS |
Directorate Appointment | 29-Feb-2024 | 07:02 | RNS |
Directorate Changes | 29-Feb-2024 | 07:01 | RNS |
Total Voting Rights | 29-Feb-2024 | 07:00 | RNS |
TR-1: NOTIFICATION OF MAJOR HOLDINGS | 28-Feb-2024 | 17:35 | RNS |
TR-1: NOTIFICATION OF MAJOR HOLDINGS | 28-Feb-2024 | 17:34 | RNS |
TR-1: NOTIFICATION OF MAJOR HOLDINGS | 28-Feb-2024 | 17:34 | RNS |
Directors’ Dealings | 26-Feb-2024 | 13:07 | RNS |
Result of General Meeting | 19-Feb-2024 | 13:52 | RNS |
Completion of Capital Reorganisation | 16-Feb-2024 | 07:00 | RNS |
Subscription | 15-Feb-2024 | 07:00 | RNS |
Capital Reorganisation | 14-Feb-2024 | 12:53 | RNS |
Notice of General Meeting & Posting of Circular | 02-Feb-2024 | 15:17 | RNS |
Convertible Loan Note Agreements | 02-Feb-2024 | 15:13 | RNS |
Currency | UK Pounds |
Share Price | 0.37p |
Change Today | 0.005p |
% Change | -1.35 % |
52 Week High | 1.43 |
52 Week Low | 0.34 |
Volume | 4,212,761 |
Shares Issued | 1,088.42m |
Market Cap | £3.97m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
14:58 | 300,000 @ 0.37p |
14:50 | 500,000 @ 0.37p |
13:53 | 13,446 @ 0.37p |
13:53 | 1,355 @ 0.37p |
13:53 | 694 @ 0.36p |
CEO | Clarissa Ann Sowemimo- Coke |
You are here: research